MabThera.com is a comprehensive resource for healthcare professionals outside the US who are interested in MabThera and the treatment of lymphomas. This site provides detailed information on MabThera, monoclonal antibody therapy, and treatment strategies for NHL and CLL.
Here you can learn more about CLL, including current theories relating to disease aetiology and current practice in diagnosis and classification.
Traditionally CLL has been considered an incurable disease and short-term responses were considered the best markers of therapy success.
Here you can learn more about NHL, including current theories relating to disease etiology and current practice in diagnosis and classification.
MabThera in combination with chemotherapy is the standard of care in NHL, offering patients with follicular disease prolonged survival and years of life free from relapse and allowing the best chance of a cure in diffuse large B cell lymphoma.
Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.
